Pfizer Inc announced the approval of a new antifungal drug, for the treatment of bloodstream infection by the FDA. The new drug called Eraxis, is indicated in the treatment of candidemia, a hospital acquired fatal blood infection.
The improved performance of Eraxis compared to Diflucan, a currently employed anti-fungal treatment is said to have supported the approval. The drug can also be used in the treatment of infections caused by Candida (a fungus), intra-abdominal abscesses, fungal infection of the esophagus and peritonitis.
The acquisition of Vicuron Pharmaceuticals Inc. by Pfizer in September is said to have set stage for acquiring Eraxis. The company's share value in the afternoon fell down to 18% ($25.65) on the New York Stock Exchange.